Cargando…

Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury

Accumulating evidence suggests that type I interferon (IFN-I) signaling is a key contributor to immune cell-mediated neuropathology in neurodegenerative diseases. Recently, we demonstrated a robust upregulation of type I interferon-stimulated genes in microglia and astrocytes following experimental...

Descripción completa

Detalles Bibliográficos
Autores principales: Todd, Brittany P., Luo, Zili, Gilkes, Noah, Chimenti, Michael S., Peterson, Zeru, Mix, Madison R., Harty, John T., Nickl-Jockschat, Thomas, Ferguson, Polly J., Bassuk, Alexander G., Newell, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436463/
https://www.ncbi.nlm.nih.gov/pubmed/37596685
http://dx.doi.org/10.1186/s40478-023-01635-5
_version_ 1785092330468933632
author Todd, Brittany P.
Luo, Zili
Gilkes, Noah
Chimenti, Michael S.
Peterson, Zeru
Mix, Madison R.
Harty, John T.
Nickl-Jockschat, Thomas
Ferguson, Polly J.
Bassuk, Alexander G.
Newell, Elizabeth A.
author_facet Todd, Brittany P.
Luo, Zili
Gilkes, Noah
Chimenti, Michael S.
Peterson, Zeru
Mix, Madison R.
Harty, John T.
Nickl-Jockschat, Thomas
Ferguson, Polly J.
Bassuk, Alexander G.
Newell, Elizabeth A.
author_sort Todd, Brittany P.
collection PubMed
description Accumulating evidence suggests that type I interferon (IFN-I) signaling is a key contributor to immune cell-mediated neuropathology in neurodegenerative diseases. Recently, we demonstrated a robust upregulation of type I interferon-stimulated genes in microglia and astrocytes following experimental traumatic brain injury (TBI). The specific molecular and cellular mechanisms by which IFN-I signaling impacts the neuroimmune response and neuropathology following TBI remains unknown. Using the lateral fluid percussion injury model (FPI) in adult male mice, we demonstrated that IFN α/β receptor (IFNAR) deficiency resulted in selective and sustained blockade of type I interferon-stimulated genes following TBI as well as decreased microgliosis and monocyte infiltration. Molecular alteration of reactive microglia also occurred with diminished expression of genes needed for MHC class I antigen processing and presentation following TBI. This was associated with decreased accumulation of cytotoxic T cells in the brain. The IFNAR-dependent modulation of the neuroimmune response was accompanied by protection from secondary neuronal death, white matter disruption, and neurobehavioral dysfunction. These data support further efforts to leverage the IFN-I pathway for novel, targeted therapy of TBI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-023-01635-5.
format Online
Article
Text
id pubmed-10436463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104364632023-08-19 Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury Todd, Brittany P. Luo, Zili Gilkes, Noah Chimenti, Michael S. Peterson, Zeru Mix, Madison R. Harty, John T. Nickl-Jockschat, Thomas Ferguson, Polly J. Bassuk, Alexander G. Newell, Elizabeth A. Acta Neuropathol Commun Research Accumulating evidence suggests that type I interferon (IFN-I) signaling is a key contributor to immune cell-mediated neuropathology in neurodegenerative diseases. Recently, we demonstrated a robust upregulation of type I interferon-stimulated genes in microglia and astrocytes following experimental traumatic brain injury (TBI). The specific molecular and cellular mechanisms by which IFN-I signaling impacts the neuroimmune response and neuropathology following TBI remains unknown. Using the lateral fluid percussion injury model (FPI) in adult male mice, we demonstrated that IFN α/β receptor (IFNAR) deficiency resulted in selective and sustained blockade of type I interferon-stimulated genes following TBI as well as decreased microgliosis and monocyte infiltration. Molecular alteration of reactive microglia also occurred with diminished expression of genes needed for MHC class I antigen processing and presentation following TBI. This was associated with decreased accumulation of cytotoxic T cells in the brain. The IFNAR-dependent modulation of the neuroimmune response was accompanied by protection from secondary neuronal death, white matter disruption, and neurobehavioral dysfunction. These data support further efforts to leverage the IFN-I pathway for novel, targeted therapy of TBI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-023-01635-5. BioMed Central 2023-08-18 /pmc/articles/PMC10436463/ /pubmed/37596685 http://dx.doi.org/10.1186/s40478-023-01635-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Todd, Brittany P.
Luo, Zili
Gilkes, Noah
Chimenti, Michael S.
Peterson, Zeru
Mix, Madison R.
Harty, John T.
Nickl-Jockschat, Thomas
Ferguson, Polly J.
Bassuk, Alexander G.
Newell, Elizabeth A.
Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
title Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
title_full Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
title_fullStr Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
title_full_unstemmed Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
title_short Selective neuroimmune modulation by type I interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
title_sort selective neuroimmune modulation by type i interferon drives neuropathology and neurologic dysfunction following traumatic brain injury
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436463/
https://www.ncbi.nlm.nih.gov/pubmed/37596685
http://dx.doi.org/10.1186/s40478-023-01635-5
work_keys_str_mv AT toddbrittanyp selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT luozili selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT gilkesnoah selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT chimentimichaels selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT petersonzeru selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT mixmadisonr selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT hartyjohnt selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT nickljockschatthomas selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT fergusonpollyj selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT bassukalexanderg selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury
AT newellelizabetha selectiveneuroimmunemodulationbytypeiinterferondrivesneuropathologyandneurologicdysfunctionfollowingtraumaticbraininjury